ES2302925T3 - Composiciones de nanoparticulas de inhibidores de proteina quinasa activada por mitogeno (map). - Google Patents
Composiciones de nanoparticulas de inhibidores de proteina quinasa activada por mitogeno (map). Download PDFInfo
- Publication number
- ES2302925T3 ES2302925T3 ES03723782T ES03723782T ES2302925T3 ES 2302925 T3 ES2302925 T3 ES 2302925T3 ES 03723782 T ES03723782 T ES 03723782T ES 03723782 T ES03723782 T ES 03723782T ES 2302925 T3 ES2302925 T3 ES 2302925T3
- Authority
- ES
- Spain
- Prior art keywords
- less
- map kinase
- composition
- inhibitor
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36552402P | 2002-03-20 | 2002-03-20 | |
| US365524P | 2002-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2302925T3 true ES2302925T3 (es) | 2008-08-01 |
Family
ID=28454669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03723782T Expired - Lifetime ES2302925T3 (es) | 2002-03-20 | 2003-03-20 | Composiciones de nanoparticulas de inhibidores de proteina quinasa activada por mitogeno (map). |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20030181411A1 (fr) |
| EP (1) | EP1490025B1 (fr) |
| JP (2) | JP4611641B2 (fr) |
| AT (1) | ATE385777T1 (fr) |
| AU (1) | AU2003230692A1 (fr) |
| CA (1) | CA2479737C (fr) |
| DE (1) | DE60319073T2 (fr) |
| ES (1) | ES2302925T3 (fr) |
| WO (1) | WO2003080024A2 (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| US20020119237A1 (en) * | 2000-12-22 | 2002-08-29 | Hevey Maurice O. | Medium and method for delivery of edible materials subject to degradation by oxidation and hydrolysis |
| EP1471887B1 (fr) | 2002-02-04 | 2010-04-21 | Elan Pharma International Ltd. | Compositions nanoparticulaires a stabilisateur superficiel de lysozyme |
| AU2003300076C1 (en) | 2002-12-30 | 2010-03-04 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| US20080045706A1 (en) * | 2002-12-31 | 2008-02-21 | Flynn Daniel L | Anti-inflammatory medicaments |
| US7279576B2 (en) * | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) * | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US20040248982A1 (en) * | 2003-06-09 | 2004-12-09 | Dyer Gordon Wayne | Use of compounds for the inhibition of proteins and UV protection |
| ATE415946T1 (de) * | 2003-08-08 | 2008-12-15 | Elan Pharma Int Ltd | Neue metaxalon-zusammensetzungen |
| EP1686962B9 (fr) | 2003-11-05 | 2012-10-03 | Elan Pharma International Limited | Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface |
| US7109163B2 (en) * | 2004-01-30 | 2006-09-19 | Ethicon, Inc. | Hemostatic compositions and devices |
| WO2006007520A1 (fr) * | 2004-07-01 | 2006-01-19 | Wisconsin Alumni Research Foundation | Composes d'hydroxybenazamide pour le traitement du cancer |
| JP2007223903A (ja) * | 2004-07-09 | 2007-09-06 | Takeda Chem Ind Ltd | 新規な固体分散体およびその製造方法 |
| AU2006235487B2 (en) | 2005-04-12 | 2011-12-22 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
| JP2008540546A (ja) * | 2005-05-10 | 2008-11-20 | エラン ファーマ インターナショナル リミテッド | ナノ粒子クロピドグレル製剤 |
| US20110064803A1 (en) * | 2005-05-10 | 2011-03-17 | Elan Pharma International Limited. | Nanoparticulate and controlled release compositions comprising vitamin k2 |
| CN101262860A (zh) * | 2005-06-03 | 2008-09-10 | 伊兰制药国际有限公司 | 纳米微粒对乙酰氨基酚制剂 |
| EA015102B1 (ru) * | 2005-06-03 | 2011-06-30 | Элан Фарма Интернэшнл Лтд. | Препараты наночастиц мезилата иматиниба |
| WO2006133045A1 (fr) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Préparations de benidipine nanoparticulaire |
| WO2008073068A1 (fr) | 2005-06-08 | 2008-06-19 | Elan Pharma International Limited | Compositions à nanoparticules et à libération contrôlée comprenant du cefditoren |
| ES2335608T3 (es) * | 2005-06-09 | 2010-03-30 | Elan Pharma International Limited | Formulaciones de ebistina nanoparticuladas. |
| MX2007015882A (es) * | 2005-06-13 | 2008-03-04 | Elan Pharma Int Ltd | Formulaciones en combinacion nanoparticulada de clopidogrel y aspirina. |
| CA2612384A1 (fr) * | 2005-06-15 | 2006-12-28 | Elan Pharma International, Limited | Formulations d'azelnidipine nanoparticulaire |
| JP2009500356A (ja) * | 2005-07-07 | 2009-01-08 | エラン ファーマ インターナショナル リミテッド | ナノ粒子クラリスロマイシン製剤 |
| JP2009507925A (ja) * | 2005-09-13 | 2009-02-26 | エラン ファーマ インターナショナル リミテッド | ナノ粒子タダラフィル製剤 |
| CA2622758A1 (fr) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Formulations aripiprazoliques nanoparticulaires |
| SG170047A1 (en) | 2006-05-30 | 2011-04-29 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations |
| KR20090018864A (ko) * | 2006-06-13 | 2009-02-23 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 키나제 억제제 제제 |
| AU2007272501A1 (en) * | 2006-07-12 | 2008-01-17 | Elan Pharma International Limited | Nanoparticulate formulations of modafinil |
| AU2008215659B2 (en) * | 2007-02-16 | 2012-11-01 | Aska Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising microparticle oily suspension |
| EP2152274A4 (fr) * | 2007-05-07 | 2010-07-21 | Questor Pharmaceuticals Inc | Administration par voie nasale de benzodiazépines |
| US8530463B2 (en) * | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
| AU2009225719A1 (en) * | 2008-03-21 | 2009-09-24 | Elan Pharma International Limited | Compositions for site-specific delivery of imatinib and methods of use |
| US20090258865A1 (en) | 2008-03-28 | 2009-10-15 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| US8110608B2 (en) | 2008-06-05 | 2012-02-07 | Ecolab Usa Inc. | Solid form sodium lauryl sulfate (SLS) pesticide composition |
| EP2172193A1 (fr) | 2008-10-02 | 2010-04-07 | Capsulution Nanoscience AG | Compositions de nanoparticules améliorées de composés faiblement solubles |
| EP3167875A1 (fr) | 2009-05-27 | 2017-05-17 | Alkermes Pharma Ireland Limited | Réduction d'agrégation de type paillettes dans des compositions de meloxicam nanoparticulaire |
| TR200904500A2 (tr) | 2009-06-10 | 2009-10-21 | Öner Levent | Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları. |
| US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
| WO2011049629A2 (fr) | 2009-10-22 | 2011-04-28 | Api Genesis, Llc | Procédés de fabrication et d'utilisation de compositions comprenant des flavonoïdes |
| US8968757B2 (en) | 2010-10-12 | 2015-03-03 | Ecolab Usa Inc. | Highly wettable, water dispersible, granules including two pesticides |
| ES2683902T3 (es) | 2011-06-14 | 2018-09-28 | Hale Biopharma Ventures, Llc | Administración de benzodiacepina |
| KR101794032B1 (ko) * | 2011-09-21 | 2017-11-07 | (주)바이오시네틱스 | 나노입자 제조방법 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
| WO2017075013A1 (fr) * | 2015-10-26 | 2017-05-04 | Eip Pharma, Llc | Méthodes et compositions pour récupérer d'un accident vasculaire cérébral |
| US11466008B2 (en) | 2017-09-18 | 2022-10-11 | Eip Pharma, Llc | Co-crystals of neflamapimod (VX-745) |
| JP2020152673A (ja) | 2019-03-20 | 2020-09-24 | 株式会社リコー | ナノ粒子及びナノ粒子の製造方法、並びに医薬 |
| EP3991750A4 (fr) * | 2019-06-26 | 2022-08-03 | Ricoh Company, Ltd. | Composition pharmaceutique |
| JP2024521399A (ja) | 2021-06-10 | 2024-05-31 | ニューレリス、インク. | 小児患者における発作性障害を治療するための組成物および方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5834025A (en) * | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| JP4107693B2 (ja) * | 1996-02-09 | 2008-06-25 | 保土谷化学工業株式会社 | 固体粒子水性懸濁液の製造方法 |
| US6361938B1 (en) * | 1996-11-08 | 2002-03-26 | Elan Corporation, Plc | Peptides which enhance transport across tissues and methods of identifying and using the same |
| WO2000012124A1 (fr) * | 1998-09-01 | 2000-03-09 | Elan Corporation, Plc | Compositions de vaccin oral |
| EP2266542A3 (fr) * | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Libération regulée de compositions nanoparticulaires |
| EP1261334A1 (fr) * | 1998-10-20 | 2002-12-04 | Omeros Corporation | Solution d'irrigation contenant des inhibiteurs de mapk et son utilisation pour traiter la douleur et l'inflammation |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US6656504B1 (en) * | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| BR0014041A (pt) * | 1999-09-17 | 2003-07-15 | Smithkline Beecham Corp | Utilização de csaids em infecção por rinovìrus |
-
2003
- 2003-03-20 EP EP03723782A patent/EP1490025B1/fr not_active Expired - Lifetime
- 2003-03-20 ES ES03723782T patent/ES2302925T3/es not_active Expired - Lifetime
- 2003-03-20 WO PCT/US2003/008547 patent/WO2003080024A2/fr not_active Ceased
- 2003-03-20 AU AU2003230692A patent/AU2003230692A1/en not_active Abandoned
- 2003-03-20 CA CA2479737A patent/CA2479737C/fr not_active Expired - Fee Related
- 2003-03-20 DE DE60319073T patent/DE60319073T2/de not_active Expired - Lifetime
- 2003-03-20 AT AT03723782T patent/ATE385777T1/de not_active IP Right Cessation
- 2003-03-20 JP JP2003577854A patent/JP4611641B2/ja not_active Expired - Fee Related
- 2003-03-20 US US10/392,303 patent/US20030181411A1/en not_active Abandoned
-
2010
- 2010-07-28 JP JP2010168818A patent/JP2010280685A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003230692A1 (en) | 2003-10-08 |
| DE60319073D1 (de) | 2008-03-27 |
| AU2003230692A8 (en) | 2003-10-08 |
| WO2003080024A3 (fr) | 2004-04-08 |
| WO2003080024A2 (fr) | 2003-10-02 |
| EP1490025B1 (fr) | 2008-02-13 |
| JP4611641B2 (ja) | 2011-01-12 |
| EP1490025A2 (fr) | 2004-12-29 |
| DE60319073T2 (de) | 2009-02-05 |
| ATE385777T1 (de) | 2008-03-15 |
| CA2479737A1 (fr) | 2003-10-02 |
| CA2479737C (fr) | 2011-05-24 |
| JP2005526785A (ja) | 2005-09-08 |
| JP2010280685A (ja) | 2010-12-16 |
| US20030181411A1 (en) | 2003-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2302925T3 (es) | Composiciones de nanoparticulas de inhibidores de proteina quinasa activada por mitogeno (map). | |
| ES2318330T3 (es) | Nuevas composiciones de metaxalona. | |
| ES2366646T3 (es) | Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial. | |
| ES2292848T3 (es) | Composiciones que tienen una combinacion de caracteristicas de liberacion inmediata y liberacion controlada. | |
| AU2010254180B2 (en) | Reduction of flake-like aggregation in nanoparticulate active agent compositions | |
| ES2341996T3 (es) | Formulaciones de mesilato de imatinib en forma de manoparticulas. | |
| ES2302035T3 (es) | Nuevas composiciones de sildenafilo en forma de base libre. | |
| US7390505B2 (en) | Nanoparticulate topiramate formulations | |
| US7998507B2 (en) | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors | |
| KR20080017065A (ko) | 나노입자형 아세트아미노펜 제제 | |
| KR20080002939A (ko) | 나노입자형 퀴나졸린 유도체 제제 | |
| BRPI0708343A2 (pt) | formulações de carvedilol nanoparticuladas | |
| WO2007146943A2 (fr) | Formulations d'inhibiteurs de kinase nanoparticulaires | |
| ES2335608T3 (es) | Formulaciones de ebistina nanoparticuladas. | |
| HK1235663A (en) | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions |